Clinical trials: NSCLC (Non-small Cell Lung Carcinoma)
NSCLC Stage IV, NSCLC Stage IIIB
1st Line Durvalumab in PS 2 NSCLC Patients
The aim of the trial is to assess efficacy and safety of the treatment with durvalumab in PS 2 patients with treatment-naïve, locally advanced or metastatic, PD-L1 positive NSCLC who are considered unsuitable for combination…
- Trial name
- NCT03620669
- Testing
- Durvalumab
- Where
- 11 sites in Switzerland
- Volunteers
- 48 people
- Sponsor
- Swiss Cancer Institute
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors…
- Trial name
- NCT04129502
- Testing
- TAK-788, Pemetrexed, Cisplatin
- Where
- 134 sites in United States, Australia and 22 more
- Volunteers
- 354 people
- Sponsor
- Takeda
Non-small Cell Lung Cancer, NSCLC
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy.
- Trial name
- NCT04245514
- Testing
- Durvalumab, Radiotherapy
- Where
- 13 sites in Germany, Switzerland
- Volunteers
- 90 people
- Sponsor
- Swiss Cancer Institute
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum…
- Trial name
- NCT05920356
- Testing
- Sotorasib, Pembrolizumab
- Where
- 424 sites in United States, Argentina and 36 more
- Volunteers
- 750 people
- Sponsor
- Amgen
NSCLC, Non Small Cell Lung Cancer
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT06552000
- Testing
- NovoTTF-200T System
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary Radiotherapy In MEtastatic Lung Cancer
Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs.
- Trial name
- PRIME-Lung (NCT07135882)
- Testing
- Radiotherapy followed by chemotherapy, Standard of Care (SOC)
- Where
- 6 sites in Australia
- Volunteers
- 420 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty.
- Trial name
- NCT07140016
- Testing
- gilteritinib
- Where
- 17 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic NSCLC - Non-Small Cell Lung Cancer
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes.
- Trial name
- NCT07149649
- Testing
- Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose
- Where
- 11 sites in Switzerland
- Volunteers
- 230 people
- Sponsor
- Swiss Cancer Institute
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer (NSCLC)
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
- Trial name
- STRADOS (NCT07432802)
- Testing
- Stereotactic radiation therapy intervention, Surgical intervention
- Where
- 4 sites in Denmark
- Volunteers
- 182 people
- Sponsor
- Aarhus University Hospital
Lung Cancer (NSCLC), KRAS G12C Lung Cancer
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib…
- Trial name
- GIVEN (NCT07472478)
- Testing
- Garsorasib, Ivonescimab Combined With Chemotherapy, Surgery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Guangdong Provincial People's Hospital
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants…
- Trial name
- NCT07680764
- Testing
- Pumitamig, Imzokitug, Pemetrexed
- Where
- 74 sites in United States, Argentina and 10 more
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
Leptomeningeal Metastasis, Breast Cancer
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
The purpose of this study is to determine the efficacy of BRain-AVOidant proton craniospinal irradiation (BRAVO pCSI) in adult participants with leptomeningeal metastases from solid tumors.
- Conditions
- Leptomeningeal Metastasis, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- BRAVO-LM (NCT07789912)
- Testing
- Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Solid Tumors, Gastric Cancer
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study.
- Conditions
- Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
- Trial name
- NCT06710132
- Testing
- M9140
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 184 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer (NSCLC)
Real-Time Non-Invasive Localization for Multiple Lung Nodules
This study compares real-time non-invasive localization and manual CT-guided needle localization for multiple lung nodules under 20 mm. It primarily aims to evaluate the successful resection rate of pulmonary nodules.
- Trial name
- NCT07257549
- Testing
- Manual needle localization, Real-time non-invasive localization
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Cachexia; Cancer, Cachexia
OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH-OLE (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 400 people
- Sponsor
- AVEO Pharmaceuticals, Inc.